Market Overview

J.P. Morgan Reiterates Overweight Rating, $26 PT on Insulet Corporation on Updated Estimates

Related PODD
Insulet Downgraded Despite Expectations For Strong Performance
Benzinga's Top Upgrades, Downgrades For July 17, 2017

In a report published Friday, J.P. Morgan reiterated its Overweight rating and $26.00 price target on Insulet Corporation (NASDAQ: PODD).

J.P. Morgan noted, “Insulet manufactures the OmniPod insulin pump system, which is a wireless, tubing-free alternative to traditional pump therapy primarily targeting Type I diabetics. We view Insulet as uniquely positioned with a differentiated offering in an under-penetrated market. Awareness of the OmniPod system continues to increase, with revenues projected to grow over 20% through 2015. Insulet recently received approval for the company's next-generation Pod, which is 30% smaller and 25% lighter, which should drive continued sales growth along with margin expansion over the next several years.”

Insulet Corporation closed on Thursday at $21.61.

Latest Ratings for PODD

Jul 2017BTIG ResearchDowngradesBuyNeutral
Jul 2017Morgan StanleyMaintainsEqual-Weight
May 2017BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Reiteration Analyst Ratings


Related Articles (PODD)

View Comments and Join the Discussion!